All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
To what extent can CPX-351 contribute to long-term remissions in high-risk AML?
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Jeffrey Lancet, Moffitt Cancer Center, Tampa, US. We asked: to what extent can CPX-351 contribute to long-term remissions in high-risk acute myeloid leukemia (AML)?
In this video, Jeffrey Lancet describes the 5-year final results of phase III study of CPX-351, a liposomal encapsulated formulation of cytarabine and daunorubicin, compared to the standard 7+3 regimen in older adults with high-risk, newly diagnosed or secondary AML. Described in the video is the overall survival, landmark analysis amongst patients that went on to receive allogeneic stem cell transplant, and complete recovery rates.
To what extent can CPX-351 contribute to long-term remissions in high-risk AML?